Cargando…

Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis

BACKGROUND: Several trials have assessed the antihyperglycemic effects of sodium/glucose cotransporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM). We conducted a quantitative analysis to assess the impact of SGLT2is on serum uric acid (SUA) in patients with T2DM. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akbari, Abolfazl, Rafiee, Mahdi, Sathyapalan, Thozhukat, Sahebkar, Amirhossein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872662/ https://www.ncbi.nlm.nih.gov/pubmed/35224108 http://dx.doi.org/10.1155/2022/7520632

Ejemplares similares

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
por: Kochanowska, Anna, et al.
Publicado: (2023)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus
por: Dong, Meiyuan, et al.
Publicado: (2023)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Clinical Importance of Wnt5a in the Pathogenesis of Colorectal Cancer
por: Pashirzad, Mehran, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients
por: Ohashi, Naro, et al.
Publicado: (2020)

Systematic Review and Meta-analysis on the Effect of Soy on Thyroid Function
por: Otun, Jemiliat, et al.
Publicado: (2019)

Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis
por: Aalami, Amir Hossein, et al.
Publicado: (2021)

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
por: Liu, Zhenghong, et al.
Publicado: (2021)

Effect of COVID-19 on Mortality of Pregnant and Postpartum Women: A Systematic Review and Meta-Analysis
por: Karimi, Leila, et al.
Publicado: (2021)

The Impact of Diabetes Mellitus in COVID-19: A Mechanistic Review of Molecular Interactions
por: Yaribeygi, Habib, et al.
Publicado: (2020)

siRNA Therapeutics: Future Promise for Neurodegenerative Diseases
por: Amiri, Atefeh, et al.
Publicado: (2021)

Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis
por: Xin, Yakai, et al.
Publicado: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
por: Cao, Yang, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus
por: Yaribeygi, Habib, et al.
Publicado: (2020)

The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review
por: Moosavian, Seyedeh Alia, et al.
Publicado: (2021)

A Comprehensive Review of the Development of Carbohydrate Macromolecules and Copper Oxide Nanocomposite Films in Food Nanopackaging
por: Mesgari, Mohammad, et al.
Publicado: (2022)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
por: Reed, James W
Publicado: (2016)

The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
por: Ito, Marie, et al.
Publicado: (2018)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
por: Sun, He, et al.
Publicado: (2023)

Sodium–glucose cotransporter-2 inhibitors in patients without diabetes
por: Fryml, Elise, et al.
Publicado: (2023)

Comparison of the Neuroprotective Effects of Aspirin, Atorvastatin, Captopril and Metformin in Diabetes Mellitus
por: Paseban, Maryam, et al.
Publicado: (2019)

Pathophysiology of Physical Inactivity-Dependent Insulin Resistance: A Theoretical Mechanistic Review Emphasizing Clinical Evidence
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Factors Influencing Change in Serum Uric Acid After Administration of the Sodium‐Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus
por: Chino, Yukihiro, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
por: Hussain, Mazhar, et al.
Publicado: (2021)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in the Treatment of Alzheimer’s Disease
por: Shahbaz, Sanaz Keshavarz, et al.
Publicado: (2022)

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Sarcopenia, frailty circle and treatment with sodium–glucose cotransporter 2 inhibitors
por: Sasaki, Takashi
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lqhhj9obegvnsk6a6jp2tqf317